281) Growth factors, gene therapy, stem cell tr |
282) ove osteoblast function by delivering two growth factors, PDGF-BB and BMP-2, incorpo |
283) ss of palatal development is regulated by growth factors, extracellular matrix (ECM) |
284) process cancer-related substrates such as growth factors, growth factor receptors, c |
285) pose tissue regeneration via secretion of growth factors, promotion of angiogenesis, |
286) o be an excellent carrier for delivery of growth factors, stem cells and other agent |
287) es have revealed a sharp decrease in root growth rates from 28% to 85%, starting fro |
288) The maximum growth rates of O. |
289) The specific growth rates of O. |
290) ce; higher acceptance patients had slower growth rates of depression across time, ev |
291) For verbs, children's growth rates were positively predicted by |
292) world scale exhibited one of the highest growth rates within animal protein product |
293) The growth arrest and DNA damage-inducible 45 |
294) trigger senescence processes, leading to growth arrest and developmental delay. |
295) GAS5 overexpression increased tumor cell growth arrest and induced apoptosis in vit |
296) or suppressor mechanism by driving stable growth arrest of cancer progenitor cells h |
297) Senescence is defined as a stable cell growth arrest. |
298) These cells exhibited maximum growth at 30 °C in L-15 medium containin |
299) The inhibitory rates of root growth at 400 ppm of SDS and GS were 85% |
300) the expression of c-Myc and arrested cell growth at G1 phase. |
301) focal brain lesions had an altered brain growth at TEA that particularly affected t |
302) and cymene completely inhibited the yeast growth at concentrations over 1 mM for a |
303) effective than ZOL at reducing xenograft growth but did not affect osteoclastic bon |
304) y simpler and allows better nutrition and growth, but is expensive for the majority |
305) and progeny genetic diversity or progeny growth, but was associated with increased |
306) recise and dynamical control of fluxes of growth-essential but byproduct pathways in |
307) ficant between-group difference in linear growth during other age-intervals. |
308) Interventions that improve fetal growth during pregnancy may have the large |
309) additional unit of BAZ) and if their BAZ growth during the first year was higher (6 |
310) plant biomass but also ameliorated plant-growth during extreme environmental condit |
311) interferon-γ, IFNG; vascular endothelial growth factor, VEGF) in oviduct and uterin |
312) issues, the level of vascular endothelial growth factor, capillary density, and angi |
313) ciated lipocalin and vascular endothelial growth factor, documented in plasma; wound |
|